LISRAYA (brepocitinib), a first-in-class oral TYK2/JAK1 inhibitor from Priovant (a Roivant company), approved for adults with dermatomyositis (Aug 27 2026).
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (3/6/26) through T+5. Run-up high $37.4 on 8/19/26, low $26.41 on 3/30/26 (T-120 to T-1). FDA decision 8/27/26. Historical price action, not a forecast.
Cohort decision-day move (history)1.0% median (n=833)
The PDUFA goal date was September 30, 2026, under Priority Review granted at the March 2026 NDA acceptance. The FDA approved on August 27, 2026, 34 days early. LISRAYA is the first targeted oral therapy approved for dermatomyositis, supported by the Phase 3 VALOR study of 241 adults. Priovant Therapeutics is a Roivant subsidiary in which Pfizer holds a stake; Pfizer originated brepocitinib.
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.